Neurocrine Biosciences Inc
NASDAQ:NBIX
Neurocrine Biosciences Inc
Operating Income
Neurocrine Biosciences Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
Operating Income
$394.8m
|
CAGR 3-Years
6%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$9.3B
|
CAGR 3-Years
32%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$8.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
See Also
What is Neurocrine Biosciences Inc's Operating Income?
Operating Income
394.8m
USD
Based on the financial report for Dec 31, 2023, Neurocrine Biosciences Inc's Operating Income amounts to 394.8m USD.
What is Neurocrine Biosciences Inc's Operating Income growth rate?
Operating Income CAGR 5Y
61%
Over the last year, the Operating Income growth was 57%. The average annual Operating Income growth rates for Neurocrine Biosciences Inc have been 6% over the past three years , 61% over the past five years .